Testing of compounds in mouse pharmacokinetic studies

THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to Charles River Laboratories, Inc., 3 Biotech, One Innovation Drive, Worcester, MA 01065. To ensure consistency among data, the current studies must be conducted by the same vendor that conducted prior testing of small molecule compounds in mouse pharmacokinetic studies for this project. Therefore, to ensure the continuity of science, this acquisition is restricted to Charles River Laboratories, Inc. DESCRIPTION The National Center for Advancing Translational Sciences (NCATS) is a part of the National Institutes of Health (NIH), with a mission to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. NCATS requires the testing of nine (9) small molecule compounds in mouse pharmacokinetic studies. These compounds are drug molecules being evaluated for a kinase inhibitor program. Testing of the compounds for their pharmacokinetic properties in mouse will provide critical information on compound clearance, exposure, and bioavailability. See the attached RFQ, Statement of Work, and other attachments for complete requirement details.